Action grants for the Computer-aided Drug Repurposing for Cancer Therapy Project
The Action grants for the Computer-aided Drug Repurposing for Cancer Therapy Project, part of the EU4Health Programme, seeks to revolutionize cancer treatment by leveraging advanced computational methods. This initiative aims to identify new effective anti-cancer drugs through 'in-silico drug repurposing,' significantly reducing development time and costs. It focuses on improving outcomes for patients with poor prognosis and rare cancers by building an EU platform based on computational drug networks.
Who is Funded
The "Action grants for the Computer-aided Drug Repurposing for Cancer Therapy Project" targets organizations and entities capable of advancing cancer therapy through innovative computational approaches within the European Union. Its primary goal is to enhance the arsenal of anticancer drugs, especially for patients with poor prognosis and rare cancers.
What is Funded
This program specifically funds projects focused on leveraging computational methods for drug repurposing in cancer therapy, with a particular emphasis on challenging cases like rare cancers. Supported activities range from concept development and piloting to establishing sustainable platforms, aiming to deliver tangible improvements in anticancer drug availability and efficacy.
Type and Scope of Funding
The program provides grants as its primary financial instrument, with a total budget of 3,000,000 € allocated for this specific topic in 2021. Further financial details and project durations are outlined in the comprehensive call documents.
Conditions and Requirements
Applicants and beneficiaries must adhere to specific conditions for application and consortium formation, as well as budget restrictions. Comprehensive details for these provisions are available in the official call documents.
Application Procedure
The application process involves a single-stage submission, followed by a comprehensive evaluation based on specific award criteria. Applicants are encouraged to consult the detailed guidelines and resources provided to ensure a successful submission.
Legal Basis
The funding program is established and governed by key European Union regulations, ensuring its legal basis and operational framework. Official texts and related documents are made publicly available for transparency and guidance.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
3,000,000 €
Allocated Budget:
3,000,000 €
Deadline:
25.01.2022
Open Until:
Ongoing
Award Channel:
Competitive Tender
Region:
European Union
Sectors:
Healthcare, Medical Technology, Pharmaceutical Industry, Research and Development, Information and Communication Technology
Beneficiaries:
Patients with poor prognosis and rare cancers
Application Type:
Consortium Required
Funding Stages:
Applied Research, Experimental Development, Prototyping, Pilot Testing, Product Development
Funding Provider
Program Level:
European Union
Funding Body:
European Union
Managed By:
European Health and Digital Executive Agency (HaDEA)
Additional Partners:
S.A.F.AN. BIOINFORMATICS - SAS DI PUGLIESE LUISA, MEDIC4ALL ITALIA S.R.L., GC GENOMICS GMBH, CLOUDPHARM PRIVATE COMPANY, Receptor LLC, GC GENOMICS ESPAÑA, SL, UNIVERSITA DEGLI STUDI DI SIENA, CONSIGLIO NAZIONALE DELLE RICERCHE, INTERSPREAD GMBH, C.I.P. CITIZENS IN POWER, Hugo Alexandre Louro Filipe, GRANT GARANT SRO, Grupo Colabora Formación y Proyectos, SL, GOLEM - GESELLSCHAFT FUR INTEGRIERTE MIKROELEKTRONISCHE KOMPLETTLOESUNGEN GMBH, IXTAL, NATIONAL CANCER INSTITUTE, Digestive Cancers Europe, BCN HEALTH ECONOMICS & OUTCOMES RESEARCH S.L., MINDS & SPARKS GMBH, Hybrid Core BV
Website: